Literature DB >> 26376993

Imaging Surveillance of Hypervascular Liver Lesions in Non-Cirrhotic Patients.

Yun Shin Chun1, Robin J Parker2, Subbarao Inampudi2, Eduardo Ehrenwald2, Kenneth P Batts3, Lawrence J Burgart3, Clark W Schumacher2, Jason A Mehling2, Bjorn I Engstrom2, Mark J Hill4, Srinevas K Reddy4, Timothy D Sielaff4.   

Abstract

A consensus surveillance protocol is lacking for non-cirrhotic patients with hypervascular liver lesions presumed to represent hepatocellular adenomas. Patients with hypervascular liver lesions <5 cm not meeting criteria for focal nodular hyperplasia or hepatocellular carcinoma underwent surveillance with contrast-enhanced magnetic resonance imaging (MRI) 6, 12, and 24 months after baseline imaging. If lesions remained stable or decreased in size, then surveillance imaging was discontinued. Between 2011 and 2014, 116 patients with hypervascular liver lesions were evaluated. Seventy-nine patients were eligible for the surveillance protocol. Median follow-up was 24 months (range, 1-144 months). One patient (1 %) continued oral contraceptive pill (OCP) use and presented with hemorrhage requiring embolization 5 months after initial diagnosis. Ten patients (13 %) underwent elective embolization or surgical resection for size ≥5 cm. The remaining 68 patients (86 %) continued surveillance without hemorrhage or malignant transformation. Risk factors for requiring intervention during the surveillance period included younger age, larger lesion size, and estrogen use (all p < 0.05). Patients with hepatocellular adenomas <5 cm can safely be observed after discontinuing OCP with serial imaging 6, 12, and 24 months after diagnosis. If lesions remain stable or decrease in size, then longer-term surveillance is unlikely to identify patients at risk for complications.

Entities:  

Keywords:  Focal nodular hyperplasia; Hepatocellular carcinoma; Liver cell adenoma

Mesh:

Year:  2015        PMID: 26376993     DOI: 10.1007/s11605-015-2942-9

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  10 in total

Review 1.  Malignant transformation of liver adenoma: an analysis of the literature.

Authors:  Olivier Farges; Safi Dokmak
Journal:  Dig Surg       Date:  2010-04-01       Impact factor: 2.588

2.  Hepatocellular adenoma subtypes: the impact of overweight and obesity.

Authors:  Paulette Bioulac-Sage; Said Taouji; Laurent Possenti; Charles Balabaud
Journal:  Liver Int       Date:  2012-03-19       Impact factor: 5.828

3.  Diagnosis and treatment of hepatocellular adenoma in the Netherlands: similarities and differences.

Authors:  S M van Aalten; T Terkivatan; R A de Man; D J van der Windt; N F M Kok; R Dwarkasing; J N M Ijzermans
Journal:  Dig Surg       Date:  2010-04-01       Impact factor: 2.588

4.  Clinical features and natural history of hepatocellular adenomas: the impact of obesity.

Authors:  C Bunchorntavakul; R Bahirwani; D Drazek; M C Soulen; E S Siegelman; E E Furth; K Olthoff; A Shaked; K R Reddy
Journal:  Aliment Pharmacol Ther       Date:  2011-07-15       Impact factor: 8.171

5.  A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas.

Authors:  Safi Dokmak; Valérie Paradis; Valérie Vilgrain; Alain Sauvanet; Olivier Farges; Dominique Valla; Pierre Bedossa; Jacques Belghiti
Journal:  Gastroenterology       Date:  2009-08-05       Impact factor: 22.682

6.  Epidemiology of hepatocellular adenoma. The role of oral contraceptive use.

Authors:  J B Rooks; H W Ory; K G Ishak; L T Strauss; J R Greenspan; A P Hill; C W Tyler
Journal:  JAMA       Date:  1979-08-17       Impact factor: 56.272

7.  Surgical management of hepatocellular adenoma: take it or leave it?

Authors:  Sung W Cho; J Wallis Marsh; Jennifer Steel; Shane E Holloway; Jason T Heckman; Erin R Ochoa; David A Geller; T Clark Gamblin
Journal:  Ann Surg Oncol       Date:  2008-08-12       Impact factor: 5.344

8.  SSAT/AHPBA joint symposium on evaluation and treatment of benign liver lesions.

Authors:  Yun Shin Chun; Michael G House; Harmeet Kaur; Evelyne M Loyer; Valérie Paradis; Jean-Nicolas Vauthey
Journal:  J Gastrointest Surg       Date:  2013-02-02       Impact factor: 3.452

9.  Management of hepatocellular adenoma: comparison of resection, embolization and observation.

Authors:  Ami M Karkar; Laura H Tang; Nilesh D Kashikar; Mithat Gonen; Stephen B Solomon; Ronald P Dematteo; Michael I D' Angelica; Camilo Correa-Gallego; William R Jarnagin; Yuman Fong; George I Getrajdman; Peter Allen; T Peter Kingham
Journal:  HPB (Oxford)       Date:  2012-10-09       Impact factor: 3.647

10.  Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy.

Authors:  Jeremiah L Deneve; Timothy M Pawlik; Steve Cunningham; Bryan Clary; Srinevas Reddy; Charles R Scoggins; Robert C G Martin; Michael D'Angelica; Charles A Staley; Michael A Choti; William R Jarnagin; Richard D Schulick; David A Kooby
Journal:  Ann Surg Oncol       Date:  2009-01-08       Impact factor: 5.344

  10 in total
  2 in total

1.  Long-term follow-up of hepatic adenoma and adenomatosis: analysis of size change on imaging with histopathological correlation.

Authors:  N Shao; A Pandey; M A Ghasabeh; P Khoshpouri; P Pandey; F N Varzaneh; M Zarghampour; D Fouladi; T M Pawlik; R A Anders; I R Kamel
Journal:  Clin Radiol       Date:  2018-07-18       Impact factor: 2.350

2.  HYPERVASCULAR LIVER LESIONS IN RADIOLOGICALLY NORMAL LIVER.

Authors:  Enio Campos Amico; José Roberto Alves; Dyego Leandro Bezerra de Souza; Fellipe Alexandre Macena Salviano; Samir Assi João; Adriano de Araújo Lima Liguori
Journal:  Arq Bras Cir Dig       Date:  2017 Jan-Mar
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.